Cited by 72Antibiotics Pharmacokinetics and EfficacyNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Altered Tissue Distribution and Elimination of Amikacin Encapsulated in Unilamellar, Low-Clearance Liposomes (MiKasome®)

Fielding, Robert M., Lewis, Ramilla O., Moon-McDermott, Lotus·1998·Pharmaceutical Research

DOI 10.1023/a:1011925132473

Open this paper in CoChat — free account

Abstract

Purpose Amikacin in small unilamellar liposomes (MiKasome) has prolonged plasma residence (half-life > 24hr) and sustained efficacy in Gram-negative infection models. Since low-clearance liposomes may be subject to a lower rate of phagocytic uptake, we hypothesized this formulation may enhance amikacin distribution to tissues outside the mononuclear phagocyte system.Methods Rats received one intravenous dose (50 mg/kg) of conventional or liposomal amikacin. Amikacin was measured for ten days in plasma, twelve tissues, urine and bile.Results Liposomal amikacin increased and prolonged drug exposure in all tissues. Tissue half-lives (63-465 hr) exceeded the plasma half-life (24.5 hr). Peak levels occurred within 4 hours in some tissues, but were delayed 1-3 days in spleen, liver, lungs and duodenum, demonstrating the importance of characterizing the entire tissue concentration vs. time profile for liposomal drugs. Predicted steady-state tissue concentrations for twice weekly dosing were >100 microg/g. Less than half the liposomal amikacin was recovered in tissues and excreta, suggesting metabolism occurred. Amikacin was not detected in plasma ultrafiltrates. Tissue-plasma partition coefficients (0.2-0.8 in most tissues) estimated from tissue-plasma ratios at Tmax were similar to those estimated from tissue AUCs.Conclusions Low-clearance liposomal amikacin increased and prolonged drug residence in all tissues compared to conventional amikacin. The long tissue half-lives suggest liposomal amikacin is sequestered within tissues, and that an extended dosing interval is appropriate for chronic or prophylactic therapy with this formulation.

Integrity signals

Registry

Crossref · 10.1023/a:1011925132473

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Renal Parenchymal Accumulation of Aminoglycoside Antibiotics in Rats
Luft, F. C., & Kleit, S. A. (1974) · The Journal of Infectious Diseases · doi:10.1093/infdis/130.6.656 · Cited by 191
Tissue Weights of the Rat. I. Normal Values Determined By Dissection and Chemical Methods
Caster, W. O., Poncelet, J., Simon, A. B., & Armstrong, W. D. (1956) · Experimental Biology and Medicine · doi:10.3181/00379727-91-22186 · Cited by 188
Long Circulating Liposomes: Old Drugs, New Therapeutics
Woodle, M. C., & Storm, G. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0 · Cited by 137
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs
Fielding, R. M., Singer, A. W., Wang, L. H., Babbar, S., & Guo, L. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.299 · Cited by 110
Self-citation
Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
Forssen, E. A., Malé-Brune, R., Adler‐Moore, J., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., & Tromberg, B. J. (1996) · PubMed · Cited by 103
Efficacy of Gentamicin or Ceftazidime Entrapped in Liposomes with Prolonged Blood Circulation and Enhanced Localization in Klebsiella pneumoniae-Infected Lung Tissue
Bakker‐Woudenberg, I. A. J. M., ten Kate, M. T., Stearne, L. E. T., & Woodle, M. C. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.4.938 · Cited by 76
Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin
Swenson, C. E., Stewart, K. A., Hammett, J. L., Fitzsimmons, W. E., & Ginsberg, R. S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.235 · Cited by 75
Formation of a cytotoxic metabolite from gentamicin by liver
Huang, M. Y., & Schacht, J. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90077-x · Cited by 69
Concepts on the Use of Liposomal Antimicrobial Agents: Applications for Aminoglycosides
Karlowsky, J. A., & Zhanel, G. G. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.4.654 · Cited by 68

Show all 19 references

Research works printed but not linked: 3

E. T. Eng. Prophylactic and therapeutic treatment of Gram-negative septicemia with liposomal and non-liposomal encapsulated amikacin in immunocompromized mice. Thesis presented to California State Polytechnic University, Pomona, CA, 1996.
W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans et al. (eds.), Applied Pharmacokinetics, 3rd edition. Applied Therapeutics, Inc., Vancouver, WA, 1992, Chapter 2.
R. M. Fielding, B. Feistner, L. Moon-McDermott, S. C. Gill, D. Roamer, and R. A. Bendele. Liposomal amikacin (Mikasome®): reduced clearance and volume of distribution in rats. Pharm. Res. 13:S-479 (1996).

Sorted by citations

“Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,920
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,620
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 992
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Nanoparticles: Emerging carriers for drug delivery
Mudshinge, S. R., Deore, A. B., Patil, S. R., & Bhalgat, C. M. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.04.001 · Cited by 557
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications
Pinto‐Alphandary, H., Andremont, A., & Couvreur, P. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00121-1 · Cited by 443
Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections
Abed, N., & Couvreur, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.009 · Cited by 365
Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 323
Self-citation
The enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E., Ferguson, E. L., & Thomas, D. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 317
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
Kingsley, J. D., Dou, H., Morehead, J., Rabinow, B. E., Gendelman, H. E., & Destache, C. J. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9032-4 · Cited by 285
Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.834-840.2002 · Cited by 242
Self-citation
Inhaled drug therapy for treatment of tuberculosis
Misra, A., Hickey, A. J., Rossi, C. R., Borchard, G., Terada, H., Makino, K., Fourie, P. B., & Colombo, P. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.08.009 · Cited by 174
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
Schiffelers, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.333 · Cited by 163
Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system
Keeling, K. M., & Bedwell, D. M. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0317-z · Cited by 149
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases
Keeling, K. M., & Bedwell, D. M. (2011) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.95 · Cited by 106
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases
Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., & McLachlan, A. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.935-942.2006 · Cited by 102
Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis
Velino, C., Carella, F., Adamiano, A., Sanguinetti, M., Vitali, A., Catalucci, D., Bugli, F., & Iafisco, M. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00406 · Cited by 98
Nano-technology for targeted drug delivery to combat antibiotic resistance
Sharma, A., Arya, D. K., Dua, M., Chhatwal, G. S., & Johri, A. K. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.717927 · Cited by 94
Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci
Bakker‐Woudenberg, I. A. J. M. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00021-3 · Cited by 66
Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007605024942 · Cited by 63
Self-citation
Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats
Marier, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg317 · Cited by 61
Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections
Bakker‐Woudenberg, I. A. J. M., Schiffelers, R. M., Storm, G., Becker, M. J., & Guo, L. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91014-8 · Cited by 50
Mechanism and evidence of nonsense suppression therapy for genetic eye disorders
Richardson, R., Smart, M. J. K., Tracey‐White, D., Webster, A. R., & Moosajee, M. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.01.001 · Cited by 48
Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities
Maxwell, A., Ghate, V., Aranjani, J. M., & Lewis, S. A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119883 · Cited by 47
Quantitation of Free and Total Amphotericin B in Human Biologic Matrices by a Liquid Chromatography Tandem Mass Spectrometric Method
Lee, J. W., Petersen, M. E., Lin, P., Dressler, D. E., & Bekersky, I. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200106000-00015 · Cited by 46
Pharmacokinetics and Urinary Excretion of Amikacin in Low-Clearance Unilamellar Liposomes after a Single or Repeated Intravenous Administration in the Rhesus Monkey
Fielding, R. M., Moon-McDermott, L., Lewis, R. O., & Horner, M. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.503 · Cited by 41
Self-citation
Fighting tuberculosis: old drugs, new formulations
Blasi, P., Schoubben, A., Giovagnoli, S., Rossi, C. R., & Ricci, M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903130577 · Cited by 40
Comparative Efficacies of Liposomal Amikacin (MiKasome) plus Oxacillin versus Conventional Amikacin plus Oxacillin in Experimental Endocarditis Induced by Staphylococcus aureus : Microbiological and Echocardiographic Analyses
Xiong, Y.-Q., Kupferwasser, L. I., Zack, P. M., & Bayer, A. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1737 · Cited by 39
Nanotechnology: a contemporary therapeutic approach in combating infections from multidrug-resistant bacteria
Brar, B., Marwaha, S., Poonia, A. K., Koul, B., Kajla, S., & Rajput, V. D. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03404-3 · Cited by 38
The activity of low-clearance liposomal amikacin in experimental murine tuberculosis
Dhillon, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.869 · Cited by 37
Pharmacokinetics, Excretion, and Mass Balance of 14C after Administration of 14C-Cholesterol-Labeled AmBisome to Healthy Volunteers
Bekersky, I., Fielding, R. M., Dressler, D. E., Kline, S., Buell, D. N., & Walsh, T. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/009127000104100906 · Cited by 35
Self-citation
Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients
Gubbins, P. O., Amsden, J. R., McConnell, S. A., & Anaissie, E. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01448-08 · Cited by 33
Pharmacokinetics and Efficacies of Liposomal and Conventional Formulations of Tobramycin after Intratracheal Administration in Rats with PulmonaryBurkholderia cepaciaInfection
Marier, J., Lavigne, J. R., & Ducharme, M. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3776-3781.2002 · Cited by 33
Colistin- and amikacin-loaded lipid-based drug delivery systems for resistant gram-negative lung and wound bacterial infections
Vairo, C., Villar-Vidal, M., Hernández, R. M., Igartúa, M., & Villullas, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122739 · Cited by 26
Advancements in Nanoparticle-Based Strategies for Enhanced Antibacterial Interventions
Moradialvand, M., Asri, N., Jahdkaran, M., Beladi, M., & Houri, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01428-0 · Cited by 23
Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases
Hong, Y., Shaw, P. J., Tattam, B. N., Nath, C. E., Earl, J. W., Stephen, K. R., & McLachlan, A. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0240-x · Cited by 22
Liposomes in the treatment of infectious diseases
Fielding, R., & Lasiç, D. D. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.12.1679 · Cited by 21
Self-citation
Recent insights on nanomedicine for augmented infection control
Singh, S., Hussain, A., Shakeel, F., Ahsan, M. J., Alshehri, S., Webster, T. J., & Lal, U. R. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s170280 · Cited by 19
Nanoparticle-based approaches for sepsis treatment: Current trends and perspectives
Louaguenouni, Y., Mansart, A., Annane, D., Fattal, E., & Fay, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114139 · Cited by 17
Antibacterial Activity of Vancomycin Encapsulated in Poly(DL-lactide-co-glycolide) Nanoparticles Using Electrospraying
Booysen, E., Bezuidenhout, M. B., Staden, A. D. P. V., Dimitrov, D., Deane, S. M., & Dicks, L. M. T. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9437-4 · Cited by 16
Use of in Vitro Critical Inhibitory Concentration, a Novel Approach to Predict in Vivo Synergistic Bactericidal Effect of Combined Amikacin and Piperacillin Against Pseudomonas aeruginosa in a Systemic Rat Infection Model
Chan, E., Zhou, S., Sahasranaman, S., & Duan, W. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9783-x · Cited by 14
Oral Administration of Nanoparticles-Based TB Drugs
Magalhães, J., Vieira, A. C. C., Santos, S. G., Pinheiro, M., & Reis, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52725-5.00016-2 · Cited by 13
Biodistribution of Amphotericin B When Delivered Through Cholesterol Hemisuccinate Vesicles in Normal and A. Fumigatus Infected Mice
Saxena, S., & Ghosh, P. C. (2000) · Pharmaceutical Research · doi:10.1023/a:1026418814417 · Cited by 13
Application of Carbon-Based Nanomaterials as Drug and Gene Delivery Carrier
Ray, S. C., & Jana, N. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47906-6.00005-9 · Cited by 12
Relationship of Pharmacokinetically-Calculated Volumes of Distribution to the Physiologic Distribution of Liposomal Drugs in Tissues: Implications for the Characterization of Liposomal Formulations
Fielding, R. M. (2001) · Pharmaceutical Research · doi:10.1023/a:1011096821662 · Cited by 12
Self-citation
Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection
Zhang, Y., & Hill, A. T. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1875821 · Cited by 11
Bio-Based Nanoemulsions: An Eco-Safe Approach Towards the Eco-Toxicity Problem
Mishra, P., Balaji, A. P. B., Mukherjee, A., & Chandrasekaran, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-48281-1_94-1 · Cited by 10
Nanoparticle-Based Drug Delivery Systems: Promising Approaches Against Bacterial Infections
Rai, A., Comune, M., & Ferreira, L. (2019) · Springer eBooks · doi:10.1007/978-981-13-9871-1_27 · Cited by 9
Bionanotechnology and bioMEMS (BNM): state-of-the-art applications, opportunities, and challenges
Borenstein, J. T., Cummins, G., Dutta, A., Hamad, E. M., Hughes, M. P., Jiang, X., Lee, H., Lei, K. F., Tang, X. S., Zheng, Y., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00296a · Cited by 9
Hepatobiliary Disposition of Liposomal Amphotericin B in the Isolated Perfused Rat Liver
Hong, Y., Ramzan, I. M., & McLachlan, A. J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20239 · Cited by 9
Bioavailability of a Small Unilamellar Low-Clearance Liposomal Amikacin Formulation after Extravascular Administration
Fielding, R. M., Moon-McDermott, L., & Lewis, R. O. (1999) · Journal of drug targeting · doi:10.3109/10611869908996848 · Cited by 9
Self-citation
M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development
Charrier, E. S. A., Dassonville‐Klimpt, A., Andréjak, C., & Sonnet, P. (2025) · Pharmaceuticals · doi:10.3390/ph18060891 · Cited by 8
Vesicular Nanomaterials: Types and Therapeutic Uses
Mahajan, S., Maji, I., Mehra, N. K., & Singh, P. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-30529-0_4 · Cited by 8
Bioresponsive dextrin-colistin conjugates as antimicrobial agents for the treatment of Gram-negative infection
Azzopardi, E. (2013) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 8
The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles
Jia, Y., Joly, H. A., Leek, D. M., Demetzos, C., & Omri, A. (2009) · Journal of Liposome Research · doi:10.3109/08982100903103896 · Cited by 5
Integrated Development of Glycobiologics: from Discovery to Applications in the Design of Nanoparticular Drug Delivery Systems
Vauthier, C., Bertholon, I., & Labarre, D. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse293 · Cited by 5
Bio-based Nanoemulsions: An Eco-safe Approach Towards the Eco-toxicity Problem
Mishra, P., Balaji, A. P. B., Mukherjee, A., & Chandrasekaran, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-68255-6_94 · Cited by 4
EVALUATING THE EFFICACY OF AMIKACIN IN LOW-CLEARANCE UNILAMELLAR LIPOSOMES IN AS. AUREUSLOCAL INFECTION MODEL
Garrison, A. E., Bendele, R., Knauer, S., Wolf, J., Moon-McDermott, L., Gill, S., & Colagiovanni, D. B. (2001) · Journal of Liposome Research · doi:10.1081/lpr-100108465 · Cited by 4
Self-citation
Understanding the Pharmacology and Pharmacotherapeutics for Infectious Diseases
Agrawal, N., Singh, I. P., Khanna, M., Dhawan, G., Kumar, P., & Dhawan, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_3 · Cited by 3
Biotechnological Approaches in Infectious Diseases
Banerjee, S., Bose, S., Shukla, A. C., & Baig, M. R. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-1148-2_15 · Cited by 3
Innovations in liposomal formulations for antimicrobial therapy
Schiffelers, R. M., & Bakker‐Woudenberg, I. A. J. M. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.8.1127 · Cited by 3
Advances in nanomaterials-assisted drug delivery, diagnosis, and action towards drug-resistant Mycobacterium
Mathur, P., Choudhary, P., Chandrasekaran, R., Singh, R., & Daima, H. K. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.11.001 · Cited by 2
Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges
Kenaan, H., Duncan, R., Al-Jamal, W. T., Jones, D. S., Andrews, G. P., Gilmore, B., Yardley, V., Farrington, N., Stott, K. E., Lawrence, D. S., et al. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100478 · Cited by 2
Exploration of Biocompatibility and Toxicity of Nanomaterials in Diagnosis and Treatment of Infectious Diseases
Puvvada, N., Chandu, B., & Panigrahi, P. K. (2025) · Wiley eBooks · doi:10.1002/9781394200559.ch11 · Cited by 2
Management of infection in children with malignancy
Miflin, G., & Kinsey, S. E. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00868-7 · Cited by 1
Medical Nanotechnology and Pulmonary Pathology
Pope‐Harman, A., & Mauro Ferrari, B. (2006) · Springer eBooks · doi:10.1007/978-0-387-25844-7_11
Formulation et évaluation de nanovecteurs polymères porteurs d'anticorps pour une délivrance ciblée d'antibiotiques.
Lê, H. (2019) · theses.fr (ABES) · doi:10.70675/5e75ee5czd722z422cz86b8z27f2b1be2f97
Immunomodulatory nanoparticles for the treatment of the inflammatory response during sepsis
Louaguenouni, Y. (2024) · theses.fr (ABES) · doi:10.70675/10de0500zcb45z4507z8ad9z3ba9e02f6822
Synthesis, Characterization, and In Vitro Evaluation of New Amino‐Alcohol Quinolines as Promising Antimycobacterial Agents
Charrier, E. S. A., Peltier, F., Raimbert, J.-F., Perret, M., Andréjak, C., Dassonville‐Klimpt, A., & Sonnet, P. (2026) · ChemMedChem · doi:10.1002/cmdc.70543
Engineering smart liposomes to combat antimicrobial resistance: from mechanistic design to clinical translation
Gawale, K., Karawadiya, A., Katawale, S., Sawarkar, S. P., & Omri, A. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2756297

Authors: Fielding, R. M., Lewis, R. O., & Moon-McDermott, L.
Corresponding author: Fielding, Robert M.
ORCID: Fielding, Robert M.
Venue: Pharmaceutical Research
Publisher: Springer Science and Business Media LLC
Published: 1998-11
Volume: 15
Issue: 11
Pages: 1775-1781
ISSN: 0724-8741 (ISSN-L)
1573-904X
DOI: 10.1023/a:1011925132473
OpenAlex: W2191567995
Cited by: 72
References: 19
Citations by year: 2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 3 · 2019: 5 · 2018: 2 · 2017: 3 · 2014: 1 · 2013: 1 · 2012: 2
FWCI: 3.42
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Pharmaceutical Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: amikacin, liposomal amikacin, unilamellar liposomes, tissue distribution, drug elimination, phagocytic uptake, extended dosing interval, aminoglycosides, gram-negative bacterial infection
MeSH terms: Amikacin, Animals, Drug Carriers, Liposomes, Male, Metabolic Clearance Rate, Tissue Distribution, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Altered Tissue Distribution and Elimination of Amikacin Encapsulated in Unilamellar, Low-Clearance Liposomes (MiKasome®)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks